Skip to main content
Top
Published in: BMC Neurology 1/2018

Open Access 01-12-2018 | Research article

Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson’s Disease Rating Scale

Authors: Anna Członkowska, Tomasz Litwin, Karolina Dzieżyc, Michal Karliński, Johan Bring, Carl Bjartmar

Published in: BMC Neurology | Issue 1/2018

Login to get access

Abstract

Background

Wilson disease is a rare genetic disorder in which impaired copper excretion results in toxic copper levels and tissue damage. Manifestations are primarily hepatic and/or neuropsychiatric, with a variety of neurological phenotypes. The aim of this study was to characterize neurological signs of Wilson disease in newly diagnosed patients and to determine whether they correlated with disability, liver function, and copper metabolism.

Methods

Fifty-three treatment-naïve patients recently diagnosed with Wilson disease who exhibited neurological symptoms were included. Neurological manifestations were characterized by examination in terms of symptom type and degree of neurological impairment (Unified Wilson’s Disease Rating Scale [UWDRS] Part III) and correlated with degree of disability (UWDRS Part II), abnormalities in copper parameters and hepatic status.

Results

Most patients (62.3%) exhibited tremor and ataxia, whereas 15.1% were dystonic, and 11.3% had parkinsonism. Discrete or unclassified signs only were observed in 11.3% of patients. A good correlation between disability (UWDRS Part II) and neurological impairment (UWDRS Part III) was observed (Pearson r = 0.84). However, there was a lack of correlation when either disability or neurological impairment were analyzed with copper parameters or liver impairment.

Conclusions

The predominant neurological manifestations in this cohort of newly diagnosed Wilson disease patients were ataxia and tremor. Neurological impairment measured was highly correlated with the level of disability. However, hepatic manifestations of Wilson disease and copper levels did not appear to be correlated with neurological status and disability. These results highlight the challenges faced when assessing Wilson disease with its highly variable symptomatology.
Appendix
Available only for authorised users
Literature
2.
go back to reference Roberts EA, Schilsky ML. American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089–111.CrossRefPubMed Roberts EA, Schilsky ML. American Association for Study of Liver Diseases (AASLD). Diagnosis and treatment of Wilson disease: an update. Hepatology. 2008;47:2089–111.CrossRefPubMed
3.
go back to reference Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G. Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transpl. 2005;11:441–8.CrossRefPubMed Dhawan A, Taylor RM, Cheeseman P, De Silva P, Katsiyiannakis L, Mieli-Vergani G. Wilson’s disease in children: 37-year experience and revised King’s score for liver transplantation. Liver Transpl. 2005;11:441–8.CrossRefPubMed
5.
go back to reference Dzieżyc K, Litwin T, Chabik G, Gramza K, Członkowska A. Families with Wilson's disease in subsequent generations: clinical and genetic analysis. Mov Disord. 2014;29:1828–32.CrossRefPubMed Dzieżyc K, Litwin T, Chabik G, Gramza K, Członkowska A. Families with Wilson's disease in subsequent generations: clinical and genetic analysis. Mov Disord. 2014;29:1828–32.CrossRefPubMed
6.
go back to reference Dziezyc K, Karlinski M, Litwin T, Członkowska A. Compliant treatment with anti-copper agents prevents clinically overt Wilson’s disease in pre-symptomatic patients. Eur J Neurol. 2014;21:332–7.CrossRefPubMed Dziezyc K, Karlinski M, Litwin T, Członkowska A. Compliant treatment with anti-copper agents prevents clinically overt Wilson’s disease in pre-symptomatic patients. Eur J Neurol. 2014;21:332–7.CrossRefPubMed
7.
go back to reference Ferenci P, Członkowska A, Merle U, Ferenc S, Gromadzka G, Yurdaydin C, Vogel W, Bruha R, Schmidt HT, Stremmel W. Late-onset Wilson’disease. Gastroenterology. 2007;132:1294–8.CrossRefPubMed Ferenci P, Członkowska A, Merle U, Ferenc S, Gromadzka G, Yurdaydin C, Vogel W, Bruha R, Schmidt HT, Stremmel W. Late-onset Wilson’disease. Gastroenterology. 2007;132:1294–8.CrossRefPubMed
8.
go back to reference Członkowska A, Tarnacka B, Möller JC, Leinweber B, Bandmann O, Woimant F, Oertel WH. Unified Wilson’s Disease Rating Scale – a proposal for the neurological scoring of Wilson’s disease patients. Neurol Neurochir Pol. 2007;41:1–12.PubMed Członkowska A, Tarnacka B, Möller JC, Leinweber B, Bandmann O, Woimant F, Oertel WH. Unified Wilson’s Disease Rating Scale – a proposal for the neurological scoring of Wilson’s disease patients. Neurol Neurochir Pol. 2007;41:1–12.PubMed
9.
go back to reference European Association for Study of Liver. EASL clinical practice guidelines: Wilson’s disease. J Hepatol. 2012;56:671–85.CrossRef European Association for Study of Liver. EASL clinical practice guidelines: Wilson’s disease. J Hepatol. 2012;56:671–85.CrossRef
10.
go back to reference Leinweber B, Möller JC, Scherag A, Reuner U, Günther P, Lang CJ, Schmidt HH, Schrader C, Bandmann O, Członkowska A, et al. Evaluation of the Unified Wilson’s Disease Rating Scale (UWDRS) in German patients with treated Wilson’s disease. Mov Disord. 2008;23:54–62.CrossRefPubMed Leinweber B, Möller JC, Scherag A, Reuner U, Günther P, Lang CJ, Schmidt HH, Schrader C, Bandmann O, Członkowska A, et al. Evaluation of the Unified Wilson’s Disease Rating Scale (UWDRS) in German patients with treated Wilson’s disease. Mov Disord. 2008;23:54–62.CrossRefPubMed
11.
go back to reference Gromadzka G, Schmidt HH, Genschel J, Bochow B, Rodo M, Tarnacka B, Litwin T, Chabik G, Członkowska A. p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease. Mov Disord. 2006;21:245–8.CrossRefPubMed Gromadzka G, Schmidt HH, Genschel J, Bochow B, Rodo M, Tarnacka B, Litwin T, Chabik G, Członkowska A. p.H1069Q mutation in ATP7B and biochemical parameters of copper metabolism and clinical manifestation of Wilson's disease. Mov Disord. 2006;21:245–8.CrossRefPubMed
12.
go back to reference Litwin T, Członkowska A. Wilson disease – factors affecting clinical presentation. Neurol Neurochir Pol. 2013;47:161–9.PubMed Litwin T, Członkowska A. Wilson disease – factors affecting clinical presentation. Neurol Neurochir Pol. 2013;47:161–9.PubMed
13.
go back to reference Poujois A, Trocello JM, Djebrani-Oussedik N, Poupon J, Collet C, Girardot-Tinant N, Sobesky R, Habès D, Debray D, Vanlemmens C, et al. Exchangeable copper: reflection of the neurological severity in Wilson’s disease. Eur J Neurol. 2017;24:154–60.CrossRefPubMed Poujois A, Trocello JM, Djebrani-Oussedik N, Poupon J, Collet C, Girardot-Tinant N, Sobesky R, Habès D, Debray D, Vanlemmens C, et al. Exchangeable copper: reflection of the neurological severity in Wilson’s disease. Eur J Neurol. 2017;24:154–60.CrossRefPubMed
14.
go back to reference Członkowska A, Litwin T, Karlinski M, Dziezyc K, Chabik G, Czerska M. D-penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease. Eur J Neurol. 2014;21:599–606.CrossRefPubMed Członkowska A, Litwin T, Karlinski M, Dziezyc K, Chabik G, Czerska M. D-penicillamine versus zinc sulfate as first-line therapy for Wilson’s disease. Eur J Neurol. 2014;21:599–606.CrossRefPubMed
15.
go back to reference Członkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson’s disease with D-penicillamine and zinc sulphate. J Neurol. 1996;243:269–73.CrossRefPubMed Członkowska A, Gajda J, Rodo M. Effects of long-term treatment in Wilson’s disease with D-penicillamine and zinc sulphate. J Neurol. 1996;243:269–73.CrossRefPubMed
16.
17.
go back to reference Oder W, Prayer L, Grimm G, Spatt J, Ferenci P, Kollegger H, Schneider B, Gangl A, Deecke L. Wilson’s disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology. 1993;43:120–4.CrossRefPubMed Oder W, Prayer L, Grimm G, Spatt J, Ferenci P, Kollegger H, Schneider B, Gangl A, Deecke L. Wilson’s disease: evidence of subgroups derived from clinical findings and brain lesions. Neurology. 1993;43:120–4.CrossRefPubMed
18.
go back to reference Ravin HA. An improved colorimetric enzymatic assay of ceruloplasmin. J Lab Clin Med. 1961;58:161–8.PubMed Ravin HA. An improved colorimetric enzymatic assay of ceruloplasmin. J Lab Clin Med. 1961;58:161–8.PubMed
19.
go back to reference Ferenci P, Steindl-Munda P, Vogel W, Jessner W, Gschwantler M, Stauber R, Datz C, Hackl F, Wrba F, Bauer P, et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson’s disease. Clin Gastroenterol Hepatol. 2005;3:811–8.CrossRefPubMed Ferenci P, Steindl-Munda P, Vogel W, Jessner W, Gschwantler M, Stauber R, Datz C, Hackl F, Wrba F, Bauer P, et al. Diagnostic value of quantitative hepatic copper determination in patients with Wilson’s disease. Clin Gastroenterol Hepatol. 2005;3:811–8.CrossRefPubMed
22.
go back to reference Machado A, Chien HF, Deguti MM, Cançado E, Azevedo RS, Scaff M, Barbosa ER. Neurological manifestations in Wilson’s disease: report of 119 cases. Mov Disord. 2006;21:2192–6.CrossRefPubMed Machado A, Chien HF, Deguti MM, Cançado E, Azevedo RS, Scaff M, Barbosa ER. Neurological manifestations in Wilson’s disease: report of 119 cases. Mov Disord. 2006;21:2192–6.CrossRefPubMed
23.
go back to reference Aggarwal A, Aggarwal N, Nagral A, Jankharia G, Bhatt M. A novel global assessment scale for Wilson’s disease (GAS for WD). Mov Disord. 2009;24:509–18.CrossRefPubMed Aggarwal A, Aggarwal N, Nagral A, Jankharia G, Bhatt M. A novel global assessment scale for Wilson’s disease (GAS for WD). Mov Disord. 2009;24:509–18.CrossRefPubMed
24.
go back to reference Weiss KH, Askari FK, Czlonkowska A, Ferenci P, Bronstein JM, Bega D, Ala A, Nicholl D, Flint S, Olsson L, Plitz T, Bjartmar C, Schilsky ML. Bis-choline tetrathiomolybdate in patients with Wilson’s disease: an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol. 2017;2:869–76.CrossRefPubMed Weiss KH, Askari FK, Czlonkowska A, Ferenci P, Bronstein JM, Bega D, Ala A, Nicholl D, Flint S, Olsson L, Plitz T, Bjartmar C, Schilsky ML. Bis-choline tetrathiomolybdate in patients with Wilson’s disease: an open-label, multicentre, phase 2 study. Lancet Gastroenterol Hepatol. 2017;2:869–76.CrossRefPubMed
25.
go back to reference Oder W, Grimm G, Kollegger H, Ferenci P, Schneider B, Deecke L. Neurological and neuropsychiatric spectrum of Wilson’s disease: a prospective study of 45 cases. J Neurol. 1991;238:281–7.PubMed Oder W, Grimm G, Kollegger H, Ferenci P, Schneider B, Deecke L. Neurological and neuropsychiatric spectrum of Wilson’s disease: a prospective study of 45 cases. J Neurol. 1991;238:281–7.PubMed
26.
go back to reference Volpert HM, Pfeiffenberger J, Gröner JB, Stremmel W, Gotthardt DN, Schäfer M, Weiss KH, Weiler M. Comparative assessment of clinical rating scales in Wilson's disease. BMC Neurol. 2017;17:140.CrossRefPubMedPubMedCentral Volpert HM, Pfeiffenberger J, Gröner JB, Stremmel W, Gotthardt DN, Schäfer M, Weiss KH, Weiler M. Comparative assessment of clinical rating scales in Wilson's disease. BMC Neurol. 2017;17:140.CrossRefPubMedPubMedCentral
27.
go back to reference Litwin T, Dusek P, Członkowska A. Neurological manifestations in Wilson’s disease – possible treatment options for symptoms. Expert Opin Orphan Drugs. 2016;4:719–28.CrossRef Litwin T, Dusek P, Członkowska A. Neurological manifestations in Wilson’s disease – possible treatment options for symptoms. Expert Opin Orphan Drugs. 2016;4:719–28.CrossRef
28.
go back to reference Hölscher S, Leinweber B, Hefter H, Reuner U, Günther P, Weiss KH, Oertel WH, Möller JC. Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease. Eur Neurol. 2010;64:83–7.CrossRefPubMed Hölscher S, Leinweber B, Hefter H, Reuner U, Günther P, Weiss KH, Oertel WH, Möller JC. Evaluation of the symptomatic treatment of residual neurological symptoms in Wilson disease. Eur Neurol. 2010;64:83–7.CrossRefPubMed
29.
go back to reference Langwinska-Wosko E, Litwin T, Dziezyc K, Karlinski M, Członkowska A. Optical coherence tomography as a marker of neurodegeneration in patients with Wilson’s disease. Acta Neurol Belg. 2017;117:867–71. Langwinska-Wosko E, Litwin T, Dziezyc K, Karlinski M, Członkowska A. Optical coherence tomography as a marker of neurodegeneration in patients with Wilson’s disease. Acta Neurol Belg. 2017;117:867–71.
30.
go back to reference Przybyłkowski A, Gromadzka G, Chabik G, Wierzchowska A, Litwin T, Członkowska A. Liver cirrhosis in patients newly diagnosed with neurological phenotype of Wilson’s disease. Funct Neurol. 2014;29:23–9. Przybyłkowski A, Gromadzka G, Chabik G, Wierzchowska A, Litwin T, Członkowska A. Liver cirrhosis in patients newly diagnosed with neurological phenotype of Wilson’s disease. Funct Neurol. 2014;29:23–9.
31.
go back to reference Litwin T, Gromadzka G, Członkowska A. Gender differences in Wilson’s disease. J Neurol Sci. 2012;312:31–5.CrossRefPubMed Litwin T, Gromadzka G, Członkowska A. Gender differences in Wilson’s disease. J Neurol Sci. 2012;312:31–5.CrossRefPubMed
32.
go back to reference Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS. Limitations of non-ceruloplasmin-bound copper in routine clinical practice. Gut. 2007;56:154.PubMedPubMedCentral Twomey PJ, Viljoen A, House IM, Reynolds TM, Wierzbicki AS. Limitations of non-ceruloplasmin-bound copper in routine clinical practice. Gut. 2007;56:154.PubMedPubMedCentral
33.
go back to reference Duncan A, Yacoubian C, Beetham R, Catchpole A, Bullock D. The role of calculated non-caeruloplasmin-bound copper in Wilson's disease. Ann Clin Biochem. 2017;54:649–54.PubMed Duncan A, Yacoubian C, Beetham R, Catchpole A, Bullock D. The role of calculated non-caeruloplasmin-bound copper in Wilson's disease. Ann Clin Biochem. 2017;54:649–54.PubMed
Metadata
Title
Characteristics of a newly diagnosed Polish cohort of patients with neurological manifestations of Wilson disease evaluated with the Unified Wilson’s Disease Rating Scale
Authors
Anna Członkowska
Tomasz Litwin
Karolina Dzieżyc
Michal Karliński
Johan Bring
Carl Bjartmar
Publication date
01-12-2018
Publisher
BioMed Central
Published in
BMC Neurology / Issue 1/2018
Electronic ISSN: 1471-2377
DOI
https://doi.org/10.1186/s12883-018-1039-y

Other articles of this Issue 1/2018

BMC Neurology 1/2018 Go to the issue